Free Trial
NASDAQ:INTS

Intensity Therapeutics Q4 2024 Earnings Results & Report

Intensity Therapeutics logo
$3.06 -0.02 (-0.49%)
As of 03:40 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Intensity Therapeutics beat analyst earnings expectations in its Q4 2024 results, released March 13, 2025. The company reported EPS of -$5.50 versus the -$5.75 consensus estimate.

Earnings Announcement Details

Quarter
Q4 2024
Report Date
Time
After Market Closes
Conference Call Date
Conference Call
7:00 PM ET

Intensity Therapeutics EPS Results

Actual EPS
-$5.50
Consensus EPS
-$5.75
Beat/Miss
Beat by +$0.25
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 7 quarters

Intensity Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Intensity Therapeutics Q4 2024 Earnings FAQ

Intensity Therapeutics (NASDAQ:INTS) reported earnings of -$5.50 per share for Q4 2024, beating the consensus estimate of -$5.75. The report was announced on Thursday, March 13, 2025.

Intensity Therapeutics Earnings Headlines

What is HC Wainwright's Estimate for INTS FY2026 Earnings?
Brookline Capital Markets Forecasts INTS FY2026 Earnings
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
Intensity (INTS) Q3 2026 Earnings Call Transcript
See More Intensity Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Intensity Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Intensity Therapeutics and other key companies, straight to your email.

About Intensity Therapeutics

Intensity Therapeutics (NASDAQ:INTS), Inc. is a clinical-stage biotechnology company developing treatments for solid tumors. Its approach centers on delivering cancer-killing agents directly into tumors, with the goal of treating the tumor while also stimulating an immune response.

The company’s lead investigational product, INT230-6, combines the chemotherapy agents cisplatin and vinblastine sulfate with a proprietary molecule intended to help the drugs spread through tumor tissue and enter cancer cells. Intensity has evaluated INT230-6 in clinical studies as a treatment for solid tumors.

Founded in 2012, Intensity Therapeutics is led by founder and Chief Executive Officer Lewis Barger. Its work is focused on developing and clinically testing its intratumoral treatment platform.

View Intensity Therapeutics Profile